Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

PURPOSE: To determine the maximum-tolerated dose (MTD) and assess safety, pharmacokinetics, pharmacodynamics, and evidence of antitumor activity of RO4929097, a gamma secretase inhibitor of Notch signaling in patients with advanced solid malignancies. PATIENTS AND METHODS: Patients received escalati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Tolcher, Anthony W., Messersmith, Wells A., Mikulski, Stanislaw M., Papadopoulos, Kyriakos P., Kwak, Eunice L., Gibbon, Darlene G., Patnaik, Amita, Falchook, Gerald S., Dasari, Arvind, Shapiro, Geoffrey I., Boylan, John F., Xu, Zhi-Xin, Wang, Ka, Koehler, Astrid, Song, James, Middleton, Steven A., Deutsch, Jonathan, DeMario, Mark, Kurzrock, Razelle, Wheler, Jennifer J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2012
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5950496/
https://ncbi.nlm.nih.gov/pubmed/22529266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.36.8282
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados